Interlude Biopharma Co, a late-stage, drug-development company focused on celiac disease, announced on Thursday the company's public launch at the 21st International Celiac Disease Symposium (ICDS 2026) and introduced plans for a prevention-focused Phase 3 trial to evaluate larazotide acetate as a therapy to protect the gut against gluten-induced injury.
Interlude expects to initiate the study in the first quarter of 2027 in the United States.
Larazotide acetate, Interlude's lead drug candidate, is an oral, locally acting peptide designed to regulate intestinal tight junctions, the gatekeepers of the intestinal barrier, by acting as a zonulin inhibitor. Because it operates at an early, upstream step before an immune response is triggered in the intestine, larazotide acetate's mechanism of action extends beyond celiac disease, offering potential therapeutic applications across any chronic inflammatory disease in which zonulin-mediated barrier dysfunction is implicated, Interlude said.
The FDA has granted Fast Track designation to larazotide acetate for the treatment of celiac disease.
ABIONYX Pharma partners with Lille University Hospital to explore CER-001 for severe burn patients
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Bambusa Therapeutics prices upsized initial public offering
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%